Abstract: A metered dose inhaler equipped with a metering valve and having an aerosol canister containing a pharmaceutical composition comprising propellant, ethanol, citric acid, and tiotropium or a pharmaceutically acceptable salt or solvate thereof dissolved in the composition, wherein the aerosol canister has an internal surface that is a non-metal material that is in contact with the pharmaceutical composition.

Abstract: A pressurized medicinal composition comprising at least 40%, by weight, of liquid carbon dioxide, a fluid that forms a homogeneous solution with liquid carbon dioxide, and at least one active pharmaceutical ingredient dissolved or suspended in the composition. The composition may have a liquid to supercritical transition temperature greater than 40° C. Also, metered dose inhalers comprising an actuator, and a canister equipped with a metering valve, wherein the canister houses a reservoir comprising a pressurized carrier fluid mixture for dissolving or suspending at least one active pharmaceutical ingredient, the carrier fluid mixture comprising liquid carbon dioxide and a second component that is a liquid at room temperature and pressure.

Abstract: Pressurized canisters coated with poly(fluoroalkylene) polymer or a copolymer of poly(fluoralkylenes) and containing a formulation comprising one or more active pharmaceutical ingredients comprising umeclidinium or a salt thereof, vilanterol or a salt thereof, or a combination of two or more of the foregoing, poly(ethylene glycol), and a propellant, inhalers comprising the pressurized canister, as well as methods of using the pressurized canisters and inhalers.

Abstract: A pressurized canister coated with poly(fluoroalkylene) polymer or a copolymer of poly(fluoralkylenes) and containing a formulation comprising one or more active pharmaceutical ingredients, PVP, and a propellant, as well as methods of using the same.

Abstract: A metered dose inhaler equipped with a metering valve and having an aerosol canister containing a pharmaceutical composition comprising propellant, ethanol, citric acid, and tiotropium or a pharmaceutically acceptable salt or solvate thereof dissolved in the composition, wherein the aerosol canister has an internal surface that is a non-metal material that is in contact with the pharmaceutical composition.

Abstract: A composition comprising particulate fluticasone or a pharmaceutically acceptable salt or solvate thereof, particulate vilanterol trifenatate, at least one of 1,1,1,2,3,3,3-heptafluoropropane and 1,1,1,2-tetrafluoroethane.

Abstract: A pharmaceutical aerosol formulation comprising particles of (a) formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof and (b) mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof dispersed in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and a bulking agent having a mass median diameter of less than one micron.